Abbott Receives Regulatory Approval for Pioneering Glucose-Ketone Monitoring Device

Abbott has secured CE Mark approval for its latest development, the FreeStyle Libre 2 Plus, a system that uniquely combines glucose and ketone monitoring. This achievement marks a significant step forward in diabetes care, providing the first integrated continuous glucose-ketone sensing technology available worldwide. According to Yahoo Finance, this approval allows the device to be marketed across Europe. The FreeStyle Libre 2 Plus sensor is designed to offer a complete picture of a user's metabolic state by tracking both glucose levels and ketone levels simultaneously. This dual functionality is particularly crucial for individuals with diabetes, as elevated ketone levels can indicate a serious condition like diabetic ketoacidosis (DKA). Traditionally, monitoring ketones has involved separate urine or blood tests, which can be inconvenient and provide only intermittent data. The new Abbott sensor simplifies this process by continuously measuring both analytes from a single device, thereby offering real-time insights that can help in preventing acute complications. This integrated approach not only enhances convenience but also provides a more dynamic understanding of the body's metabolic responses. The FreeStyle Libre 2 Plus builds upon Abbott's established FreeStyle Libre technology, which has revolutionized glucose monitoring for millions of people with diabetes by eliminating the need for routine fingerpricks. By adding ketone monitoring, the company aims to further empower patients and healthcare professionals with more actionable data for improved disease management. Experts suggest that continuous ketone monitoring, alongside glucose tracking, can play a vital role in identifying periods of metabolic stress or insulin deficiency earlier, allowing for timely intervention. This could ultimately reduce hospitalizations and enhance the overall quality of life for individuals living with diabetes, particularly those with Type 1 diabetes who are at higher risk of DKA. The company anticipates a positive impact on global diabetes care with the rollout of this advanced technology.